Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice.

Abstract

BACKGROUND:

Only few data are available on the efficacy of tigecycline in critically ill patients.

METHODS:

This prospective, multicenter, non-interventional study investigated the efficacy and safety of tigecycline in hospitalized, severely ill patients with complicated intra-abdominal infections (cIAI) and/or complicated skin and soft tissue infections (cSSTI). Documentation included diagnosis, clinical findings, Acute Physiology and Chronic Health Evaluation II score, laboratory assessments, surgery, clinical outcomes, and adverse events.

RESULTS:

Six hundred and fifty-six patients (mean Acute Physiology and Chronic Health Evaluation II score 19.1) with cIAI (41%), cSSTI (16%), multiple infection sites (13%) and/or other severe infections (31%) received tigecycline - 51% as monotherapy - due to failure of previous antibiotics (55%) or since resistant pathogens were suspected or proven (45%); clinical cure/improvement rates were 75, 82, 76 and 67% for cIAI, cSSTI, other severe infections and multiple infection sites, respectively. Drug-related adverse events occurred in 6.7% of patients.

CONCLUSIONS:

The efficacy and safety of tigecycline was demonstrated in a population of severely ill patients with complicated infections.

• Authors: Christian Eckmann, Wolfgang R Heizmann, Eva Leitner, Christof von Eiff, Klaus-Friedrich Bodmann
• Journal: Chemotherapy (Chemotherapy) Vol. 57 Issue 4 Pg. 275-84 ( 2011) ISSN: 1421-9794 [Electronic] Switzerland
• PMID: 21778715 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 S. Karger AG, Basel.

Chemical References

• Anti-Bacterial Agents
• Tigecycline
• Minocycline

Topics

• Aged
• Anti-Bacterial Agents (adverse effects, therapeutic use)
• Escherichia coli (pathogenicity)
• Female
• Germany
• Humans
• Infections (complications, drug therapy, microbiology)
• Male
• Middle Aged
• Minocycline (adverse effects, analogs & derivatives, therapeutic use)
• Prospective Studies
• Severity of Illness Index
• Soft Tissue Infections (drug therapy)
• Staphylococcal Skin Infections (drug therapy)
• Staphylococcus aureus (pathogenicity)
• Tigecycline
• Treatment Outcome